vote.vitadao.com Open in urlscan Pro
2400:52e0:1e00::1081:1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

snapshot
Connect wallet


VITADAO


1.3K members
Join

Proposals

About

Settings





PROPOSALS


New proposal

0xe6Fe...9C77
Core

Active


VDP-130 [GOVERNANCE]: VITA-FAST COMMUNITY GROWTH AND OPERATIONAL SUPPORT
PROPOSAL

Summary This proposal aims to allocate a budget of up to $50,000 for the
VITA-FAST community to support its expansion and operational needs. The
VITA-FAST initiative is centered on governing Autophagy research in
collaboration with the Viktor Korolchuk Lab at Newcastle University. This
funding will facilitate direct community interaction with the lab's pioneering
work. Background The VITA-FAST community is engaged in the governance of
Autophagy research, a critical area in longevity science. The community
leverages VITA-FAST tokens to interact with and support the Korolchuk Lab's
efforts to discover compounds that promote autophagy and cellular rejuvenation.
Proposal We propose the following allocation of funds: Community Growth: up to
$40,000 To be utilized for initiatives that will increase community engagement
and membership. Operational Support: up to $10,000 To cover the essential
operational costs that enable the community to function effectively. Rationale
The allocation is designed to enhance the VITA-FAST community's capacity to
support vital research and ensure sustainable operations. This proposal
recognizes the community's potential to contribute significantly to longevity
research and the importance of maintaining robust operational support.
Deliverables A strategic plan for the utilization of the community growth funds.
An operational budget outline detailing the allocation of support funds. Funding
Request The total funding requested is up to $50,000, to be released from the
VitaDAO treasury subject to approval. Conclusion By approving this proposal,
VitaDAO will strengthen the VITA-FAST community's role in advancing Autophagy
research, thereby contributing to the overarching goal of promoting human
longevity.

Ends in 7 days - 61.12% quorum reached

0xe6Fe...9C77
Core

Active


VDP-128 [GOVERNANCE] THE NETWORK STEWARD ROLE

Summary Proposing Laurence Ion for a Network Steward role Motivation Zuzalu.city
was a huge success. Laurence Ion was one of the Core Organizers, along with
Vitalik Buterin. He also initiated Vitalia.city, a network society designed for
the VitaDAO community to coordinate in physical locations as well, with the
ability to govern its laws and regulations and run decentralized clinical trials
in a better regulatory framework. He transitioned out of the Dealflow Steward
role, as he was mostly needed for strategic activities, like fundraising,
recruiting, building relationships, advocacy (speeches, interviews, etc),
community building & in-person gatherings. Specification The responsibilities
will include: Maintain engagement with new and current strategic members and
contributors Advocate for our mission at events, conferences and in interviews
Grow VitaDAO’s in-person presence & coordination Negotiate with governments for
progressive and permissive jurisdictions to create longevity cities / zones and
inspire existing states to become the “Silicon Valley” of Longevity General
business development Strategic support Representing token holders as a delegate
Implementation Upon passing of this proposal, Laurence Ion will have the Network
Steward role. We are drafting further proposals to complete the picture,
including an assessment of Vitalia.city.

Ends in 5 days - 61.62% quorum reached

0xe6Fe...9C77
Core

Active


VDP-129 [ASSESSMENT]: VITALIA - A CITY THAT BUILDS LONGEVITY COMPANIES

One-liner: Vitalia.city is a city that accelerates the development of longevity
biotech. Simple Summary Vitalia.city is a movement to start a longevity network
city. The city will be distributed into 3-5 hubs in different special economic
zones. In these hubs, we build companies and work on the technology and science
to make death optional. The MVP is a 2-month “pop-up city”, like Zuzalu.city.
With the upcoming gathering, we aim to give people a taste of what it’s like to
live in close proximity with 200+ like-minded people for 2 months, with the goal
of having 20+ permanent residents stay over and incubate 10-15 new
companies/projects. The upcoming pop-up city is happening between Jan 6 - Mar 1,
2024 on the Caribbean island of Roatán, with one of the districts being in the
Próspera Special Economic Zone, where clinical trials can be run orders of
magnitude faster and cheaper. image6.jpg Problem image2.png There are formidable
barriers to bringing potential medicines to market. Progress is strangulated by
over-regulation. Animal models are not good predictive models. Instead of
Moore’s Law, we have the inverse, Eroom’s Law (coined by Jack Scannell; Nature
paper) Opportunity VitaDAO is an online network, but we cannot give people
online drugs. We need locations for faster trials. Semi-autonomous zones for an
in-person community to govern itself, trying a better regulatory framework,
where self-experimentation is allowed, enabling potential treatments (that are
stuck in the 10+ year-long approval pipeline) to save millions of lives. This is
paramount for achieving longevity escape velocity within 1-3 decades. Creating
new cities is a bold vision. A world-class medical innovation zone is desirable
for host countries, providing win-win economics. The return profile is
unprecedented. Longevity already is a $tn opportunity by itself, with Vitalia
capturing equity value primarily as an accelerator for new companies. The
value-add for the incubated companies is the location (land value appreciation)
and the community (token economy). The land upside has a venture-scale return
profile but with downside protection. Vitalia will own cheap land and
differential upside on sub-leasing (in places like Próspera). Initially, the
funds will be held in one “mothership” entity that focuses on 1) community
development, 2) company acceleration, and 3) land & jurisdictional business
development. As Vitalia grows, it will create two more entities for the
different risk profiles: a) a VC fund and B) a real estate and land development
fund (similar to Próspera). It will also act as a service provider, capturing up
to 7% of each district’s governance token (similar to Molecule) image4.jpg
image1.png image3.jpg image5.jpg Relevance to longevity Providing a “warp speed”
pathway for longevity therapeutics will radically accelerate progress toward
achieving extended healthy human lifespans for all. Financing Vitalia is raising
a $1M pre-seed round at a $10M post-money valuation cap via a SAFE note, and has
reserved up to $200K for the VitaDAO community. Additional information Deck**:
https://docsend.com/view/uzkh4r4vsjcfknzc 5-min presentation** at Balaji
Srinivasan’s The Network State Conference 2023:
https://twitter.com/vita_dao/status/1719054445940502767

Ends in 4 days - 61.49% quorum reached

0xe6Fe...9C77
Core

Active


VDP-126 [ASSESSMENT] REMEDIUM BIO

Remedium Bio is a regenerative medicine biotechnology company, which has
developed the only dose adjustable gene therapy platform technology Prometheus™
and is currently advancing multiple assets with uncorrelated risk to
Investigational New Drug (IND) approval. Longevity Dealflow WG Team Senior
reviewers**: 2 biotech entrepreneurs and 3 biotech VC Shepherd**: Paolo Binetti
Squad members**: Ryan Spangler, Tovah Wolf Sourced by**: Paolo Binetti via
lifespan.io Longevity Investor Network Project PI Frank Luppino, founder & CEO**
Simple Summary Remedium is a regenerative medicine biotech focused on
age-related diseases and large unmet clinical needs* . Remedium has multiple
assets targeting large unmet clinical needs that show advantages over currently
approved products, with significant benefits to healthspan. The company has also
developed a platform gene delivery technology that overcomes limitations of
current generation technologies, with the potential to revolutionize therapeutic
protein delivery. Prometheus™ is delivered as a simple subcutaneous injection,
remains highly localized, and provides durable expression while offering
functionality not available with other gene delivery technologies. The platform
can deliver a wide range of genetic cargo using a non-antigenic vector and can
be easily re-dosed to augment treatment or down-titrated to reduce the level of
therapeutic transgene expression. Remedium’s lead candidate is a first-in-class
disease modifying regenerative treatment for Osteoarthritis (OA). The treatment
augments expression of an endogenous protein, FGF18, that is critical to the
formation and maintenance of healthy cartilage, levels of which are known to
decline with age. A single intra-articular injection turns back the clock in the
joint, resulting in unprecedented efficacy in a translatable model of primary
OA. Besides knee OA, the Prometheus™ platform is in active preparation for
licensing to large pharma and biotech companies and has been evaluated as a
first-in-class single injection treatment for obesity and Type 2 diabetes (T2D),
where it is promoting weight loss*, *improving glucose control, and insulin
tolerance in a well-established preclinical model of the disease. Remedium’s
treatment results in similar efficacy to currently commercially approved ‘daily’
incretins, while minimizing pharmacokinetic sawtoothing, which may drastically
improve the treatment’s safety and tolerability. The Problem Osteoarthritis OA
is the largest unmet need in rheumatology and the leading cause of joint
replacements. To date, however, only one therapeutic approach, repeat and
continual FGF18 injections have demonstrated the ability to increase cartilage
thickness in placebo controlled clinical studies, while also demonstrating
improvement in symptom progression and a complete arrest of progression to joint
replacement surgery. That treatment modality, however, is limited by
pharmacokinetics of the joints. Since cartilage is avascular, local treatment is
required, however, therapeutics delivered locally are rapidly cleared from the
joint, limiting efficacy. As such, FGF18 protein injections require up to 12
injections per year in bilateral OA and may need to be sustained indefinitely to
prevent reversal of cartilage loss. An ideal approach would utilize a
therapeutic that works (FGF18) and deliver it in a means that would produce
efficacy without being pharmacokinetically limited by rapid washout (Fig 1).
Picture1.jpg Protein-based treatments and Gene Therapy Protein-based treatments
have revolutionized medicine, however, they remain expensive to develop and
administer and are limited by pharmacokinetic sawtoothing, which results in
peaks and troughs that limit safety and efficacy of repeat protein injection
therapies. Gene therapy has the potential to solve these issues, but current
generation technologies are extremely expensive and doses cannot be adjusted up
or down following initial administration. Moreover, once a gene therapy
treatment is administered it cannot be discontinued, preventing its use as a
protein replacement therapy (Fig 2). Picture2 (1).jpg Type 2 diabetes and
Obesity GLP1 Receptor agonists (GLP1-RAs) have revolutionized treatment of Type
2 diabetes and obesity. Despite their success, however, they remain expensive,
and are limited by gastrointestinal side effects that result in a nearly 70%
discontinuation rate after the first year of treatment (Fig 3). The side effects
have been attributed to the pharmacokinetic spikes following treatment, which do
not appear necessary to achieve therapeutic efficacy. Eliminating the
pharmacokinetic spikes and reducing the need for daily or weekly injections
would result in significant improvements in treatment adherence, maximizing the
benefits of this therapy. Picture3.jpg The Solution RMD1101 Regenerative
Treatment for OA RMD1101 is a single, intra-articular injection delivering the
FGF18 transgene to arthritic joints, facilitating regeneration that has been
confirmed in a clinically translatable model of OA. The single injection
treatment of RMD1101 was able to preserve cartilage and subchondral bone
geometry in the destabilized medial meniscus model of OA. RMD1101 demonstrated
dose-dependent increases in cartilage thickness relative to the placebo control
(PBS) as well as compared with the positive control (FGF18 protein treatment,
rhFGF18) (Fig 4). Picture4.jpg RMD1101 also showed improved safety, as shown in
Fig 5. Picture5.jpg The breadth and consistency of response to RMD1101 are
unprecedented in the treatment of OA and demonstrated in Fig 6 showing histology
from all joints collected in the in vivo efficacy study. There is clear and
extensive degeneration in the vehicle / PBS treated joints (top row) and
near-normal cartilage appearance of the RMD1101 / High Dose gene therapy treated
joints (bottom row). Picture6.jpg Prometheus™ Dose Adjustable Gene Therapy
Platform Remedium has developed the solution to the challenges constraining gene
therapies (unadjustability of the treatment dose following initial
administration) and recombinant protein treatments (cost and pharmacokinetic
sawtoothing caused by repeat injections). The Prometheus™ dose adjustable gene
therapy platform (Fig 7) technology for the first time enables the replacement
of a number of subcutaneous protein injection therapies as a single injection.
The treatment is durable, adjustable, highly localized, does not impact any
life- or function-sustaining organ and is non-antigenic, facilitating re-dosing.
Most importantly, the treatment can be easily scaled and produced at a fraction
of the cost of even the current protein therapies. Picture7.jpg In vivo testing
of Prometheus™ confirms its ability to deliver transgenes to the subcutis and
that the treatment can be easily augmented by repeat dosing, following initial
administration (Fig 8). Studies show the treatment remains durable over a period
of half a year, without any observed transgene expression decline. The mechanism
for enabling said durability, delivery vector, genetic constructs, and means of
dose adjustment are proprietary and exclusive to Remedium. Picture8.jpg
Moreover, the system can be easily down-titrated following initial
administration. Fig 9 shows reduction of reporter gene expression in a
dose-dependent manner. This can be accomplished via pharmacological or physical
methods that are safe and exceptionally well tolerated. As the technology is
highly scalable, a single treatment cost could be as low as $50 per injection at
scale. Remedium is currently advancing this platform to in vivo efficacy and
finalizing the licensing package to enable partnerships with large pharma and
biotech companies in the first half of 2024. Picture9.jpg Prometheus™ has a
large cargo capacity and is versatile: initial proof of concept studies have
demonstrated the ability to express incretins (GLP1 Receptor Agonists), insulin,
and full-length monoclonal antibodies. Future efforts will focus on
supplementation of longevity factors, suppression of chronic inflammation, and
enzyme replacement therapies (Fig 10). Picture10.jpg RMD1202 Treatment for
Obesity and Type 2 diabetes Remedium’s second pipeline asset is an innovative
treatment for Obesity and Type 2 diabetes, utilizing Prometheus™. RMD1202 has
been evaluated in a well-established high fat diet (HFD) and Streptozotocin
induced model of late-stage Type 2 diabetes, where it has demonstrated the
ability to deliver the same efficacy as daily Exenatide (GLP-1 Receptor Agonist)
injections over the 4-wk study period. Statistically significant improvement in
weight loss, and glucose / insulin tolerance relative to control are shown in
Fig 11. Picture11.jpg The treatment produced the aforementioned efficacy on top
of an outstanding safety profile and is anticipated to nearly completely
eliminate pharmacokinetic spikes associated with repeat GLP-1 RA peptide
injections, which are the main drivers of gastrointestinal side-effects causing
treatment discontinuation. Thus, the approach is anticipated to be not only cost
effective and simpler to administer, but also better tolerated. Opportunity OA
is the largest unmet clinical need in rheumatology and is estimated to impact 1
in 7 adults, as the leading cause of joint replacements worldwide. The market
for OA and related treatments are estimated at over $50B globally (Fig. 12).
Picture12.jpg Type 2 diabetes and Obesity are highly prevalent conditions that
adversely impact longevity and healthspan. Current estimates place the market
for T2D and Obesity at over $30B US. The ability of the platform to replace
monoclonal therapies, treatments for diabetes and rheumatoid arthritis, atopic
dermatitis, enzyme replacement therapies, and augment lost protein expression to
enhance longevity can result in a plethora of highly lucrative partnerships for
the company. Relevance to Longevity As we age, several critical to function
genes decline in the level and quality of gene expression. A number of them,
such as FGF18, FGF21, and Alpha-Klotho, have been implicated in promoting
healthspan and lifespan. Prometheus™ is an effective method of replacing
proteins adversely impacted by age-related decline, whereas traditional gene
therapy approaches are immunogenic, extremely expensive, cannot be re-dosed, and
cannot be adjusted following initial administration. Remedium’s lead candidate
is a regenerative therapy for the treatment of OA, a characteristic disease of
aging where cartilage is lost over time causing loss of joint function. Remedium
technology is therefore well positioned to prevent health related decline in the
age-related degenerative pathology of the joint and translate to other areas of
healthspan and lifespan. IP Roadmap Remedium maintains a robust IP portfolio for
its lead OA gene therapy, and pipeline products. To enable the optimal level of
IP protection, Remedium has contracted Wolf Greenfield, a biotech-focused IP
firm with specific expertise in gene therapy. The Remedium team has extensive
and diversified expertise ideating, drafting, submitting, and defending IP with
nearly 190 patents and pending applications. IP is ideated internally and
Remedium performs internal freedom to operate and patentability assessments
prior to preparing provisional applications. Its lead OA PCT has been published
and is in national filing stages. In addition, Remedium has a portfolio of 7
provisional patents covering the lead indication, platform technology, and
pipeline assets that enable extensive protection of its innovative technology.
See the pipeline in Fig. 13. Picture13.jpg Planning and Milestones The series-A
two-year planning to bring the three key assets to clinical trials is provided
in Fig. 14. Picture14.jpg Budget Remedium is currently raising a $15M Series A
round. Through the end of 2024, Remedium is planning the following use of
capital: OA IND-enabling work: $6.3M focused on toxicology batch production,
IND-enabling preclinical study completion, and preparation of the IND
submission. PrometheusTM Development: $2.0M focused on full platform
characterization and enablement of licensing for partnered therapeutic
indications. General R&D and SG&A: $1.8M to support pipeline assets and
operational activities including R&D, Operations, External Manufacturing,
Quality, and Regulatory. BD, IP, Software, Office, Misc: $1.1M to support
partnership activities, IP advancement to national phases and PCT applications,
software, office space and other expenses. Remedium has developed 3 assets and a
platform technology through in vivo efficacy on a total initial raise of
approximately $3.5M and plans to continue highly efficient use of capital into
the future to maximally extend runway and enable maximum value creation for the
investors. Financing and VitaDAO Fundings Terms Remedium was founded in 2021 and
raised an expanded seed round of approximately $3.5M, of which over $1M was
committed by the CEO. All funds to date have been invested as a SAFE (20%
discount, $25M cap). Remedium is a Delaware corporation, currently raising a
Series A, targeting a $15M raise and has identified a reputable VC to lead the
round. Remedium’s current investors include the LongevityTech Fund,
MicroVentures, Angel Star Ventures, Primo Medical Group, Sherwood Ventures, Apis
Health Angels, Guindy Alumni Angels, as well as several prominent angel
investors who are/were former biotech industry executives. For a limited time,
Remedium is continuing to accept investments under the SAFE to bridge closing of
the Series A. An allocation of $50k is available for VitaDAO community. Team The
team has over 50 years experience in biotechnology with a focus on biologics,
regenerative medicine, and gene therapy. The leadership is comprised of seasoned
industry executives who have a track record taking companies from a market cap
of $6M to $1B and developing / industrializing / licensing products to global
pharma and biotech giants including JNJ, Bohringer Ingelheim, and Sanofi (Fig.
15). Picture15.jpg The company has additionally hired a cadre of top clinical
and scientific advisors in the therapeutic areas of focus. Their advisors have a
wealth of scientific expertise in the disease areas, extensive experience in
clinical development, and the clinical background necessary to drive product
design (Fig. 16). Picture16.jpg Pitch Slide Deck:
https://drive.google.com/open?id=1n-wE_j4YrS50g9LhmdhCx6ZvUIFcSJuH&usp=drive_fs
Pitch recording:
https://drive.google.com/file/d/12cfxJ52I487emQmDN5pKefHInNUqZgVK/view
Highlights Prometheus™:** a unique platform technology capable of delivering
peptides to antibodies as a single injection, adjustable dose gene therapy, at a
fraction of the cost of current treatment, applicable to a wide range of
potential longevity interventions. RMD1101:** regenerative gene therapy for the
treatment of Osteoarthritis based on the only clinically validated mechanism of
therapeutic activity – FGF18. RMD1202:** single injection, which performs as
well as daily GLP-1 RA injections in a translatable model of T2D, without the
pharmacokinetic spikes that drive the discontinuation causing side effects.
Team:** the leadership team is comprised of seasoned industry veterans with
extensive background successfully developing, industrializing, facilitating
approval, and licensing blockbuster therapies. Risks Risks for Remedium Bio are
standard corporate risks associated with a preclinical biotech including:
Manufacturing / CMC Toxicology IND-enabling studies Regulatory financing risks
associated with the current market environment Remedium has undertaken several
risk mitigation strategies to reduce risk associated with its programs,
including: 1) Utilization of 2 contract development and manufacturing
organizations to scale-up the lead candidate product and produce Toxicology /
IND-enabling preclinical study batch. 2) Completion of extensive
biodistribution/safety/efficacy testing in relevant preclinical models to
maximally derisk IND-enabling GLP studies. 3) Utilization of proven
technological elements with clinical level validation, e.g. the FGF18 transgene
has been clinically confirmed as functional in a placebo controlled randomized
trial. 4) Pursuit of a tiered intellectual property strategy where multiple
technological elements (e.g. formulations, doses, genetic constructs) are
protected in subsequent applications to optimally secure IP. 5) Maximally
efficient use of funds through reliance on academic collaborations for research
and development activities with internalization of only critical to function
staff. References Please see the Discourse proposal for the list of references.
Senior Review Digest - Quantitative Below is the average scores out of 5 per
category from 5 reviewers, who all recommended that the project should be
advanced for token-holders vote. Average Scores Team Expertise: 4.4 Feasibility
& Data: 4.0 Commercial Potential & Impact: 4.6 Novelty & Market Advantage: 4.0
IP Defensibility: 3.5 Relevance to Longevity: 4.0 Deal Terms: 3.6 General
Conviction Score 4.2** (for reference, the average score of past funded projects
is 3.7) Senior Review Digest - Qualitative Each reviewer was asked whether they
would endorse the project, below are their answers. Reviewer 1 I would suggest
funding the project, mainly because of its potential applications in gene
therapy and longevity therapeutics. It could provide a safer way for several
gene therapies. Additionally, VitaDAO could think of finding synergies with
other portfolio companies as a gene delivery system and so on. Reviewer 2 I like
the concept of innovative platforms, but with the little information I have
right now I would be hesitant to support it. That's mainly driven by the poor
understanding of the platform technology, so once that has been cleared, I
could. Reviewer 3 Yes, based on what little i know, I'm very excited about this
project. Reviewer 4 Yes, for a 50k check. Advice is to wait for a lead investor
because this project will need a large amount of capital to hit the key value
inflection milestone. Reviewer 5 Yes. In fact, I am planning to introduce a
corporate venture and two funds to consider investing

Ends in 3 days - 84.8% quorum reached

0xe6Fe...9C77
Core

Closed


VDP-127: VITADAO AMBASSADOR INITIATIVE

Summary: The VitaDAO Community Ambassador Initiative is designed to empower
mission-aligned individuals globally to foster community growth, engage in
outreach, and host in-person events, promoting VitaDAO's vision of decentralized
funding for early-stage longevity research. Relevance to Strategic Plan: This
initiative aligns with VitaDAO’s primary strategic goals of: Amplifying
Community Engagement and Size. Enhancing Brand Awareness within General and
Niche Audiences. Encouraging Decentralized Governance and Participation.
Motivation: By tapping into the power of localized communities, we aim to
promote VitaDAO's values, increase VITA token utility and awareness, and spur
meaningful in-person interactions. This aligns with the foundational principles
of Ethereum and web3—empowering communities to drive change. Ambassador Squad
Core Team: @alexdobrin @Alex @m_marinova @estherk @Adrian Matysek, Andreas
Melhede, @gweisha Decentralized Governance Framework: Ambassadors will report to
the Ambassador squad core team, but all major decisions related to budgets, and
modifications to the program will be presented to VitaCore. Ambassador Criteria:
Successfully undergo a screening process including a call to verify identity.
Conversational proficiency in English. Submission of a comprehensive plan for
their Ambassador activities. Completion of VitaDAO training modules. Preferred:
Local ties to communities such as academic research, biohacking, web3, venture,
etc. Organisations and university societies can act as partner or ambassador
organisations. They would organised joint events and not require ambassador
compensation because we are sponsoring their event and community. Event Approval
and Governance: Events need pre-approval by the Ambassador squad and VitaDAO.
Approval is based on the initiative’s budget, strategic alignment, event
proposal, and the Ambassador’s past records. Compensation and Reimbursement:
Event Budget Compensation can be claimed after a successful event. Payment
bounty ranging from $100 - $200 USD, with bonuses based on attendance and views.
A referral and commission mechanism will be considered for future
implementation. Bounties may be added for valuable conversions, e.g., new
regular contributors. Implementation Metrics: Quantitative: Number of events: 5
per month Attendees per event: 20-40 Recurring attendees: Min 15% Ambassadors
recruited: Min 10 Local communities engaged: 10 Academic institutions
partnerships: 3-5/quarter Qualitative: Institution quality: Vetted by unbiased
team members. Community feedback: 1-5 star rating system with feedback
provision. Budget Proposal: Total 6-month budget: 21,750 USDC & 9,500 vested
VITA tokens Ambassador squad compensation: 6,750 USDC Event Reimbursements: Up
to $750 per event (based on 10 ambassadors with 2 events each) Ambassador
Compensation: Up to $200 per event (based on performance metrics and dependent
on geographic location). Option for bonuses on multiple or highly successful
events in strategic locations. Team Rewards: 1,500 VITA (based on 10 VITA/hr and
additional performance incentives) Airdrops for New Contributors: Up to 150 VITA
per event Conclusion: By adopting this proposal, VitaDAO aims to merge the best
of decentralized governance with community-driven outreach, fostering genuine
growth and enhancing its global footprint.

For 2M VITA
100%

Against 0 VITA
0%

Abstain 0 VITA
0%

Ended 9 hours ago - 176.63% quorum reached

0xe6Fe...9C77
Core

Closed


VDP-121 PROPOSAL TO MINT UP TO 10% OF TOTAL TOKEN SUPPLY

Summary The Tokenomics Squad proposes to mint up to 10% of total token supply in
new vested VITA for new strategic contributors. Team Todd White, Alex Dobrin
Motivation VitaDAO’s growth is tracking to the 2023 Strategic Plan, and in the
case of the Dealflow Working Group, the working group has exceeded its internal
target of 1 project funding per month, with 12 projects funded in the past 9
months. While VitaDAO has an operational budget through to June 2024, it is
desirable to maintain the momentum of the Dealflow Working Group and community
growth initiatives, and ensure sufficient resources will be available to take
advantage of opportunities. At the same time, VitaDAO’s community is being
frequently approached by institutional biotech and web3 entities interested in
Longevity and Decentralised Science (“DeSci”) and are looking for ways to
participate. The 2023 Strategic Plan outlines the launch of the VitaDAO
Accredited Investor Fund (VDAIF) which is anticipated in Q4 of this year. The
fund will be token-gated thereby increasing demand for VITA tokens to allow for
participation. Purchasing VITA on DEXs is impossible for these entities in high
enough volume. The Tokenomics Squad members believe it would be beneficial to
grow the DAO treasury and include these entities. Specification The current
minted supply of VITA is 25,719,552. We propose to mint up to 6,429,888 VITA, or
10% of the total token supply, bringing the minted supply to 32,149,440, or 50%
of the Total Token Supply of 64, 298,880 . This will be used to provide
allocations to new strategic contributors. Implementation The Coordination
Working Group will mint up to an additional 6,429,888 VITA, as required, and
maintain it in a ring fenced multisig to maintain distinction from VitaDAO’s
main treasury activities. Once completed, this proposal authorises the
Coordination Working Group to undertake a process similar in format to VDP-54
and VDP-58 for the allocation of the tokens. Budget No additional budget is
required for this proposal. Costs are already anticipated within the
Coordination Working Group operational budget. It is anticipated that there may
be additional legal costs similar to those outlined in VDP-58 upon formalising
the token allocations to strategic contributors.

For 1.8M VITA
95.32%

Against 41K VITA
2.14%

Abstain 49K VITA
2.55%

Ended 4 weeks ago - 167.32% quorum reached